Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | One Broadway, 14Th Floor CAMBRIDGE MA 02142 |
Tel: | N/A |
Website: | https://www.merrimack.com |
IR: | See website |
Key People | ||
Gary L. Crocker Chairman of the Board, President, Treasurer |
Business Overview |
Merrimack Pharmaceuticals, Inc. is a biopharmaceutical company. The Company does not have any ongoing research or development activities and is seeking potential acquirers for its remaining preclinical and clinical assets. The Company is entitled to receive contingent payments related to its sale of ONIVYDE to Ipsen S.A. and also its contingent payments related to its sale of MM-121 and MM-111 to Elevation Oncology, Inc. Its payments are payable by Ipsen upon approval by the United States Food and Drug Administration (FDA) of ONIVYDE for certain additional clinical indications. ONIVYDE is approved by the FDA in combination with fluorouracil (5-FU) and leucovorin (LV) for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy. The Company's wholly owned subsidiaries include Merrimack Pharmaceuticals UK Limited and Merrimack Securities Corporation. |
Financial Overview |
For the fiscal year ended 31 December 2023, Merrimack Pharmaceuticals Inc revenues was not reported. Net loss decreased 24% to $1.2M. Lower net loss reflects Interest income increase from $188K to $868K (income), General and administrative - Balancing v decrease of 5% to $2M (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$0.11 to -$0.08. |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $195.47M as of Dec 31, 2023 |
Annual revenue (TTM): | $0.00M as of Dec 31, 2023 |
EBITDA (TTM): | -$2.18M as of Dec 31, 2023 |
Net annual income (TTM): | -$1.18M as of Dec 31, 2023 |
Free cash flow (TTM): | -$1.52M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 14,531,760 as of Mar 15, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |